| Name | AG 1295 |
| Description | AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4]. |
| In vitro | AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1]. |
| In vivo | AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibiting PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly decreases interstitial fibrosis, as evidenced by a smaller Sirius-Red stained area, fewer macrophages, reduced ED-A+ fibronectin deposition, and fewer alpha-smooth muscle actin-positive cells[4]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (256.08 mM), Sonication is recommended.
|
| Keywords | RTK | Platelet-derived growth factor receptor | PDGF-receptor | PDGFR | Inhibitor | inhibit | autophosphorylation | AG-1295 | AG1295 | AG 1295 |
| Inhibitors Related | Regorafenib monohydrate | Sunitinib | Nintedanib | Imatinib Mesylate | Toceranib Phosphate | Sorafenib | Nintedanib esylate | Regorafenib | Lenvatinib mesylate | Lenvatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |